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Abstract 
Background: The 12-lead electrocardiographic screening for the prevention of sudden cardiac death in young com-
petitive athletes is not cost-effective and thus not routinely recommended. We investigate whether a less expensive 
wireless electrocardiographic transmission device can be used to screen for the prevention of sudden cardiac death 
in this population.
Methods: During pre-participation screening, twenty college football players underwent two electrocardiograms: 
a conventional 12-lead electrocardiogram and a wireless 9-lead electrocardiogram. We compared several electrocar-
diographic parameters (QRS duration, left ventricular hypertrophy using the Cornell voltage criteria and the Sokolow–
Lyon criteria, ST deviation and corrected QT interval) to determine the correlation.
Results: The QRS duration, left ventricular hypertrophy using the Cornell voltage criteria and the Sokolow–Lyon 
criteria and corrected QT interval exhibited significant correlation between the two types of electrocardiograms (cor-
relation coefficient 0.878, 0.630, 0.770 and 0.847, respectively with P values of 0.01, 0.003, 0.01 and 0.01, respectively). 
ST deviation in V1 was weakly correlated between the two types of electrocardiograms without statistical significance 
(correlation coefficient 0.360 with a P value of 0.119).
Conclusions: Our newly developed wireless 9-lead electrocardiogram demonstrated significant correlations with 
a conventional 12-lead electrocardiogram in terms of QRS duration, left ventricular hypertrophy and corrected QT 
interval.
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Background
Sudden cardiac death among young competitive athletes 
was reported occurring in 0.46 per 100,000 athletes per 
academic year in high school grade 10–12 in Minnesota 
[1]. In the United States, the most common cause of sud-
den cardiac death among athletes has been reported as 
hypertrophic cardiomyopathy (26.4  %) [2]. An observa-
tional study in Italy showed that sudden cardiac death in 
young athletes aged 12–35 years occurred in 2.3 athletes 
per 100,000 per year [3]. Arrhythmogenic right ventricu-
lar cardiomyopathy was the most common cause (22.4 %) 
of sudden cardiac death in Italian athletes [4].
The 12-lead electrocardiogram (ECG) for the screen-
ing of sudden cardiac death in young competitive athletes 
is recommended by the European Society of Cardiol-
ogy (ESC), but not by the American Heart Association 
(AHA) and American College of Cardiology (ACC) [4, 
5]. The ESC recommended mandatory 12-lead ECG for 
sudden cardiac death screening in young competitive 
athletes based on the Italian study conducted by Corrado 
et  al. [6], which showed a 79  % relative risk reduction 
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attributed to screening. In Europe, the cost of a 12-lead 
ECG is roughly 10 Euros (1 Euro is approximately 1.36 
dollars as of January 2014) [4]. In the United States, how-
ever, the cost of a 12-lead ECG is expected to be 39–47 
Dollars according to the Medicare and Outpatient Pro-
spective Payment Systems institutional reimbursement 
rates [7]. A cost-projection model showed that the cost 
per life saved would be between 10.6 and 14.4 million 
Dollars in the United States [7].
A less expensive wireless electrocardiographic trans-
mission device could make screening feasible for the pre-
vention of sudden cardiac death. A new 9-lead wireless 
electrocardiographic transmission device was developed 
by a physicist at the University of Illinois at Urbana-
Champaign. We investigated whether this new 9-lead 
ECG could be used to screen for the prevention of sud-
den cardiac death in young competitive athletes.
Methods
Screening population
Football players at the University of Illinois at Urbana-
Champaign were enrolled for the pre-participation 
screening in our study. We held a meeting with freshman 
football athletes in the absence of their coaches during 
the pre-participation screening for the 2013–2014 sea-
son. We explained our study objectives, protocols and 
benefits and answered their concerns and questions. 
Written informed consent was obtained from each ath-
lete. Twenty freshman college football players at the Uni-
versity of Illinois at Urbana-Champaign were enrolled 
in our pilot study. They were free to withdraw from our 
study at anytime.
New 9‑lead wireless electrocardiographic transmission 
device
A physicist at the University of Illinois at Urbana-
Champaign has invented a new 9-lead wireless elec-
trocardiographic transmission device (Fig.  1). The 
electrocardiogram produced by this device is obtained 
using 9 leads, lead I, II, III, aVR, aVL, aVF, V1, V3 and V6 
(Fig. 2). The device utilizes 9 leads similar to the conven-
tional 12-lead ECG, omitting lead V2, V4 and V5. There 
are a total of 12 electrodes, 3 of them limb electrodes, 3 
of them chest electrodes and 6 of them reference elec-
trodes (Fig. 3). The IOLab device was designed to be an 
inexpensive wireless transmission device for teaching, 
but its low cost, coupled with its battery operation and 
flexible expansion port, makes it ideal as a low-noise 
electrical data-recording device.
Screening process
During pre-participation screening for the 2013–2014 
season, 20 freshman college football players at the 
University of Illinois at Urbana-Champaign under-
went two ECGs. Each athlete underwent a conventional 
12-lead ECG screening, followed by the new 9-lead ECG 
screening on the same day. The results from the conven-
tional 12-lead ECGs were printed and numbered and the 
results from the 9-lead ECGs were wirelessly transmitted 
to a secure server and numbered the same as the respec-
tive 12-lead ECGs.
Electrocardiographic parameters
We compared several electrocardiographic parameters 
between the two ECGs. To screen for pre-excitation syn-
drome, arrhythmogenic right ventricular cardiomyopathy 
and bundle branch blocks, we measured and compared 
the QRS durations between the two ECGs. For hyper-
trophic cardiomyopathy and left ventricular hypertrophy 
(LVH), two criteria were used: the Cornell voltage crite-
ria (R wave in lead aVL + S wave in lead V3 >2.8 mV) and 
the Sokolow–Lyon criteria (S wave in lead V1 +  R wave 
in lead V6 >3.5 mV). To screen for Brugada syndrome and 
arrhythmogenic right ventricular cardiomyopathy, the ST 
deviation in lead V1 was measured and compared. For 
the screening of long QT and short QT syndrome, the 
corrected QT intervals were checked. The electrocardio-
graphic parameters were measured in a blinded manner 
Fig. 1 The new wireless 9-lead electrocardiographic transmission 
device.
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using serial numbers. Calipers were used to measure the 
electrocardiographic parameters on the 12-lead ECG 
and a digital ruler was utilized to measure the electrocar-
diographic parameters on the 9-lead ECG. The abnormal 
findings of 12-lead ECGs for the athletes are summarized 
in Table 1.
Statistical methods
We used Pearson’s correlation coefficient to compare the 
electrographic parameters between the two ECGs. The 
linear correlation of the electrocardiographic param-
eters was analyzed using the SPSS Statistics version 19. 
The correlation coefficients ranged from −1.0 to +1.0, 
with −1.0 and +1.0 representing a perfect negative and 
a perfect positive correlation, respectively. As the value 
approaches to 1.0, the correlation becomes stronger and 
a value between 0.5 and 1.0 indicates a strong correlation. 
The P value for the each comparison was calculated to 
determine the statistical significance of the results.
Institutional Review Board
This study was approved by the Institutional Review 
Board at the University of Illinois at Urbana-Champaign, 
Fig. 2 A 9-lead ECG obtained from the new electrocardiographic device.
Fig. 3 Lead placement for the new 9-lead electrocardiographic 
recording.
Page 4 of 6Cho et al. BMC Res Notes  (2015) 8:342 
#12354. The new wireless electrocardiographic transmis-
sion device was also approved by the Institutional Review 
Board at the University of Illinois at Urbana-Champaign 
to be safe for testing in athletes.
Results
QRS duration
We measured the longest QRS duration on the 12-lead 
and 9-lead ECGs. The correlation coefficient was calcu-
lated as 0.878 with a P value of 0.01 (Fig.  4), indicating 
that the QRS duration strongly correlated between the 
two ECGs.
Left ventricular hypertrophy
We compared LVH using the Cornell voltage and 
Sokolow–Lyon criteria on the two ECGs. The correla-
tion coefficient was measured as 0.630 with a P value of 
0.003 for the Cornell voltage criteria (Fig.  5). The cor-
relation coefficient was 0.770 with a P value of 0.01 for 
the Sokolow–Lyon criteria (Fig. 6). Both of the compari-
sons showed strong correlation between the two ECGs to 
detect LVH.
ST deviation
We compared the ST deviation of lead V1 on the two 
ECGs. The correlation coefficient was calculated as 0.360 
with a P value of 0.119 (Fig. 7). The correlation was weak 
without the statistical significance. On most of the ECGs, 
there was no appreciable ST deviation.
QT prolongation
We compared the corrected QT intervals between the 
two ECGs to screen for long QT and short QT syndrome. 
We calculated the corrected QT intervals by dividing the 
QT interval by the root square of the RR interval. The 
correlation coefficient was 0.847 with a P value of 0.01 
(Fig.  8), indicating that the correlation is significantly 
positive.
Table 1 Abnormal 12-lead ECG findings of the twenty ath-
letes
Abnormal findings Athlete  
number
Detail
QRS duration >120 ms 1 Pre-excitation syndrome 
(140 ms and delta wave)






ST deviation >0.1 mV 0
QTc interval >440 ms 0
Fig. 4 The correlation coefficient and correlation graph of each 
electrocardiographic parameter. The QRS duration on the 12-lead 
ECG (horizontal axis) and the 9-lead ECG (vertical axis).
Fig. 5 The correlation coefficient and correlation graph of each elec-
trocardiographic parameter. The left ventricular hypertrophy using 
the Cornell voltage criteria on the 12-lead ECG (horizontal axis) and 
the 9-lead ECG (vertical axis).
Fig. 6 The correlation coefficient and correlation graph of each elec-
trocardiographic parameter. The left ventricular hypertrophy using 
the Sokolow–Lyon criteria on the 12-lead ECG (horizontal axis) and 
the 9-lead ECG (vertical axis).
Page 5 of 6Cho et al. BMC Res Notes  (2015) 8:342 
Discussion
The prevention of sudden cardiac death in young com-
petitive athletes with a conventional 12-lead ECG contin-
ues to be controversial. We applied our newly-developed 
9-lead wireless electrocardiographic transmission device 
to obtain equivalent information at lower cost. Our new 
device has 9 leads and wirelessly transmits the data to 
a secure server, which could pave the way to rendering 
ECG-based screening inexpensive and widely available. 
This was a pilot study to validate the usefulness of our 
new electrocardiographic device by comparing vari-
ous electrocardiographic parameters between the two 
ECGs. Our new 9-lead ECG was comparable to the con-
ventional 12-lead ECG in detecting widened QRS com-
plexes, LVH and corrected QT abnormalities. A widened 
QRS complex can be used to screen for pre-excitation 
syndromes, arrhythmogenic right ventricular cardiomyo-
pathy and bundle branch blocks. The Cornell voltage or 
Sokolow–Lyon criteria can be used to screen for LVH 
and hypertrophic cardiomyopathy. Prolonged or short-
ened corrected QT intervals can be used to detect long 
QT or short QT syndrome.
The most common cause of sudden cardiac death in 
young competitive athletes in the United States is hyper-
trophic cardiomyopathy (26.4  %), followed by commo-
tio cordis (19.9  %), coronary artery anomalies (13.7  %), 
LVH of indeterminate cause (7.5 %), myocarditis (5.2 %), 
ruptured aortic aneurysm (3.1 %), arrhythmogenic right 
ventricular cardiomyopathy (2.8  %), bridged coronary 
artery (2.8  %), aortic valve stenosis (2.6  %), atheroscle-
rotic coronary artery disease (2.6 %), dilated cardiomyo-
pathy (2.3  %), myxomatous mitral valve degeneration 
(2.3  %), asthma (2.1  %), heat stroke (1.6  %), drug abuse 
(1.0 %), other cardiovascular causes (1.0 %) and long QT 
syndrome (0.8  %) [2]. Among these causes, only hyper-
trophic cardiomyopathy, LVH, arrhythmogenic right ven-
tricular cardiomyopathy and long QT syndrome can be 
screened using a conventional 12-lead ECG. Our study 
demonstrated that the new 9-lead ECG is equivalent to 
the 12-lead ECG in determining these parameters.
There are a few limitations to our study. First, our 
device is not yet commercially available and thus we 
cannot determine how much it will cost. However, 
because our device is simple, small and records using 
only 9 leads, it would be much less expensive than con-
ventional electrocardiographic machines. When we 
have the cost of our device determined, we will ana-
lyze the cost-effectiveness of our device. Second, we 
included only a small cohort of athletes, which might 
not be sufficient to validate these ECG results for the 
overall athlete population. This is a pilot study and we 
are planning to include a larger number of athletes in 
baseball, basketball, football and ice hockey. We are 
also planning to check LVH with echocardiogram to 
determine how well our wireless transmission device 
predicts LVH. We are planning to broaden our study to 
check exercise-induced ECG changes along with heart 
rate variability and signal-averaged ECG. We need more 
testing to ensure that our device can provide us the 
same quality of ECGs while athletes are doing activities 
of daily living or even exercising. Third, the ST devia-
tion in lead V1 only showed a weak correlation between 
the two ECGs. We know that the ST deviation in lead 
V1 varies depending on the lead placement and the 
causes of sudden cardiac death which can be detected 
by ST deviation in lead V1 are only Brugada syndrome 
and arrhythmogenic right ventricular cardiomyopahty. 
Brugada syndrome is a rare cause of sudden cardiac 
death and arrhythmogenic right ventricular cardiomy-
opathy only comprises 2.8  % of sudden cardiac death 
in the United States. Thus this weak correlation of ST 
Fig. 7 The correlation coefficient and correlation graph of each 
electrocardiographic parameter. The ST deviation in lead V1 on the 
12-lead ECG (horizontal axis) and the 9-lead ECG (vertical axis).
Fig. 8 The correlation coefficient and correlation graph of each elec-
trocardiographic parameter. The corrected QT interval on the 12-lead 
ECG (horizontal axis) and the 9-lead ECG (vertical axis).
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deviation in lead V1 will not affect the overall validity of 
our device.
The new 9-lead wireless electrocardiographic transmis-
sion device is still under investigation and modification. 
Our device is very convenient to use and apply. We are 
planning to apply our device while the athletes are doing 
activities of daily living and even exercising in the field. 
This convenience of testing will be another advantage of 
having wireless transmission system of our device. The 
measurement of the various electrocardiographic param-
eters is easy to perform with zooming and panning func-
tions of the digital ruler. Cloud computing will allow us 
to create population norms and to compare ECGs for 
the same athlete. A significant value would trigger a fur-
ther analysis by a physician and result in further work-up 
such as echocardiogram. Because only a small number of 
ECGs would need a physician reading, this device could 
be potentially less expensive than conventional 12-lead 
ECG. We hope that this new device will improve the 
cost-effectiveness of electrocardiographic screening for 
the prevention of sudden cardiac death in young com-
petitive athletes.
Conclusions
Our newly developed wireless 9-lead electrocardiogram 
demonstrated significant correlations with a conventional 
12-lead electrocardiogram in terms of QRS duration, left 
ventricular hypertrophy and corrected QT interval.
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